Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
Endocrine

15-09-2024 | Metformin | Review

Clinical outcomes in type 2 diabetes patients with chronic heart failure treated with metformin: a meta-analysis

Authors: Wenxia Huang, Rongchen Zhao

Published in: Endocrine

Login to get access

Abstract

Objective

To explore outcomes of metformin (Met) as an antihyperglycemic agent in patients with type 2 diabetes mellitus (T2DM) combined with chronic heart failure (CHF).

Methods

This article employed a meta-analysis approach to systematically search several databases. Stata 15.1 software was employed for statistical analysis.

Results

This meta-analysis encompassed 15 randomized controlled trials, involving 20,595 patients with T2DM and CHF. The results revealed that in comparison to the non-Met group, the Met group exhibited a significantly reduced risk of all-cause mortality (RR = 0.72, 95%CI: 0.60–0.87) and a notably lower risk of cardiovascular mortality (RR = 0.52, 95%CI:0.29–0.92). However, there was no significant difference in the risk of hospitalization due to heart failure (RR = 0.85, 95%CI: 0.70–1.04). Furthermore, the Met group demonstrated significant improvements in NT-proBNP levels compared to the non-Met group (WMD = −132.91, 95%CI: −173.03, −92.79). Regarding the enhancement of Left Ventricular Ejection Fraction and Left Ventricular End-Diastolic Dimension levels, no statistically significant differences were observed between the two groups.

Conclusion

In individuals with T2DM and CHF, the use of Met is linked to a decreased likelihood of all-cause mortality and cardiovascular-related mortality. Furthermore, it can enhance cardiac function in CHF patients without elevating the risk of hospitalization due to heart failure, establishing its safety and potential benefits.
Literature
1.
D.J. Magliano, E.J. Boyko, committee IDAtes. International Diabetes Federation; 2021. 10th ed. Brussels.2021.
2.
I.S. Thrainsdottir, T. Aspelund, T. Hardarson, K. Malmberg, G. Sigurdsson, G. Thorgeirsson et al. Glucose abnormalities and heart failure predict poor prognosis in the population-based Reykjavik Study. Eur. J. Cardiovasc Prev. Rehabil. 12, 465–471 (2005)CrossRefPubMed
3.
J.B. Buse, D.J. Wexler, A. Tsapas, P. Rossing, G. Mingrone, C. Mathieu et al. 2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diab. Care 43, 487–493 (2020)CrossRef
4.
R.I. Misbin, L. Green, B.V. Stadel, J.L. Gueriguian, A. Gubbi, G.A. Fleming, Lactic acidosis in patients with diabetes treated with metformin. N. Engl. J. Med. 338, 265–266 (1998)CrossRefPubMed
5.
S.E. Inzucchi, F.A. Masoudi, D.K. McGuire, Metformin in heart failure. Diab. Care 30, e129 (2007)CrossRef
6.
A.A. Tahrani, G.I. Varughese, J.H. Scarpello, F.W. Hanna, Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ 335, 508–512 (2007)CrossRefPubMedPubMedCentral
7.
A. Holstein, E.H. Egberts, [Traditional contraindications to the use of metformin – more harmful than beneficial?]. Dtsch Med Wochenschr. 131, 105–110 (2006)CrossRefPubMed
8.
J.N. Cohn, R. Ferrari, N. Sharpe, Cardiac remodeling–concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J. Am. Coll. Cardiol. 35, 569–582 (2000)CrossRefPubMed
9.
M.R. MacDonald, M.C. Petrie, N.M. Hawkins, J.R. Petrie, M. Fisher, R. McKelvie et al. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur. Heart J. 29, 1224–1240 (2008)CrossRefPubMed
10.
11.
R. Harris, J. Deeks, D. Altman, M. Bradburn, R. Harbord, J. Sterne, Metan: fixed- and random-effects meta-analysis. Stata J. 8, 3–28 (2008)CrossRef
12.
13.
M. Egger, Davey, G. Smith, M. Schneider, Bias in meta-analysis detected by a simple, graphical test. Br. Med. J. 315, 629–634 (1997)CrossRef
14.
S. Duval, R. Tweedie, Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56, 455–463 (2000)CrossRefPubMed
15.
R. Roussel, F. Travert, B. Pasquet, P.W. Wilson, S.C. Smith Jr., S. Goto et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch. Intern Med 170, 1892–1899 (2010)CrossRefPubMed
16.
P. Liu, X.C. Zhou, T. Wang, Clinical study of Dapagliflozin in the treatment of type 2 diabetes complicated with heart failure. Chin. J. Clin. Pharmacol. 37, 227–230 (2021)
17.
R.F. Hua, Q. Shu, Y. Liu, X.B. Zeng, L. Ji, B.Q. Xie et al. Efficacy of sitagliptin metformin combination with insulin in the treatment of obesity type 2 diabetes with heart failure. Shanghai Med. J. 37, 862–864 (2014)
18.
Y. Su, D. Wang, J. Long, F. Yang, Q. Xu, L.Y. Si, Clinical study of Metformin improving cardiac function in patients with type 2 diabetes complicated with diastolic heart failure. J. Third Mil. Med. Univ. 35, 1862–1865 (2013)
19.
C. Andersson, J.B. Olesen, P.R. Hansen, P. Weeke, M.L. Norgaard, C.H. Jorgensen et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia 53, 2546–2553 (2010)CrossRefPubMed
20.
J. Wang, Y. Lu, X. Min, T. Yuan, J. Wei, Z. Cai, The association between metformin treatment and outcomes in type 2 diabetes mellitus patients with heart failure with preserved ejection fraction: A retrospective study. Front Cardiovasc Med 8, 648212 (2021)CrossRefPubMedPubMedCentral
21.
A. Retwinski, M. Kosmalski, M. Crespo-Leiro, A. Maggioni, G. Opolski, P. Ponikowski et al. The influence of metformin and the presence of type 2 diabetes mellitus on mortality and hospitalisation in patients with heart failure. Kardiol. Pol. 76, 1336–1343 (2018)CrossRefPubMed
22.
H.Y. Chang, Y.W. Su, A.N. Feng, M.C. Fong, K.C. Huang, E. Chong et al. Prescription patterns of diabetes medications influencing clinical outcomes of heart failure patients with reduced ejection fraction. ESC Heart Fail 7, 604–615 (2020)CrossRefPubMedPubMedCentral
23.
F.A. Masoudi, S.E. Inzucchi, Y. Wang, E.P. Havranek, J.M. Foody, H.M. Krumholz, Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 111, 583–590 (2005)CrossRefPubMed
24.
D.T. Eurich, S.R. Majumdar, F.A. McAlister, R.T. Tsuyuki, J.A. Johnson, Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diab. Care 28, 2345–2351 (2005)CrossRef
25.
J.M. Evans, A.S. Doney, M.A. AlZadjali, S.A. Ogston, J.R. Petrie, A.D. Morris et al. Effect of Metformin on mortality in patients with heart failure and type 2 diabetes mellitus. Am. J. Cardiol. 106, 1006–1010 (2010)CrossRefPubMed
26.
J. Benes, M. Kotrc, K. Kroupova, P. Wohlfahrt, J. Kovar, J. Franekova et al. Metformin treatment is associated with improved outcome in patients with diabetes and advanced heart failure (HFrEF). Sci. Rep. 12, 13038 (2022)CrossRefPubMedPubMedCentral
27.
T.R. Godec, D.I. Bromage, M. Pujades-Rodriguez, A. Cannata, A. Gonzalez-Izquierdo, S. Denaxas et al. Cardiovascular outcomes associated with treatment of type 2 diabetes in patients with ischaemic heart failure. ESC Heart Fail 9, 1608–1615 (2022)CrossRefPubMedPubMedCentral
28.
D. Aguilar, W. Chan, B. Bozkurt, K. Ramasubbu, A. Deswal, Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ. Heart Fail 4, 53–58 (2011)CrossRefPubMed
29.
D.D. Shah, G.C. Fonarow, T.B. Horwich, Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J. Card. Fail 16, 200–206 (2010)CrossRefPubMed
30.
Group UPDS, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 854–865 (1998)CrossRef
31.
L. Facila, O. Fabregat-Andres, V. Bertomeu, J.P. Navarro, G. Minana, S. Garcia-Blas et al. Metformin and risk of long-term mortality following an admission for acute heart failure. J. Cardiovasc Med (Hagerstown) 18, 69–73 (2017)CrossRefPubMed
32.
A. Halabi, J. Sen, Q. Huynh, T.H. Marwick, Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis. Cardiovasc Diabetol. 19, 124 (2020)CrossRefPubMedPubMedCentral
33.
34.
X.F. Wang, J.Y. Zhang, L. Li, X.Y. Zhao, H.L. Tao, L. Zhang, Metformin improves cardiac function in rats via activation of AMP-activated protein kinase. Clin. Exp. Pharm. Physiol. 38, 94–101 (2011)CrossRef
35.
M.J. Crowley, C.J. Diamantidis, J.R. McDuffie, C.B. Cameron, J.W. Stanifer, C.K. Mock et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: A systematic review. Ann. Intern Med 166, 191–200 (2017)CrossRefPubMedPubMedCentral
36.
N. Papanas, E. Maltezos, D.P. Mikhailidis, Metformin and heart failure: never say never again. Expert Opin. Pharmacother. 13, 1–8 (2012)CrossRefPubMed
37.
38.
39.
P.M. Seferovic, M.C. Petrie, G.S. Filippatos, S.D. Anker, G. Rosano, J. Bauersachs et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail 20, 853–872 (2018)CrossRefPubMed
40.
A.M. Stades, J.T. Heikens, D.W. Erkelens, F. Holleman, J.B. Hoekstra, Metformin and lactic acidosis: cause or coincidence? A review of case reports. J. Intern Med 255, 179–187 (2004)CrossRefPubMed
41.
Authors/Task Force M, T.A. McDonagh, M. Metra, M. Adamo, R.S. Gardner, A. Baumbach et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail 26, 5–17 (2024)CrossRef
Metadata
Title
Clinical outcomes in type 2 diabetes patients with chronic heart failure treated with metformin: a meta-analysis
Authors
Wenxia Huang
Rongchen Zhao
Publication date
15-09-2024
Publisher
Springer US
Published in
Endocrine
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-024-04025-6

EASD 2024

‘Noninferior’ reduction of type 1 diabetes HbA1c by weekly insulin efsitora alfa

Weekly treatment with insulin efsitora is noninferior to daily insulin degludec for the reduction of HbA1c in adults with type 1 diabetes, show the findings of the QWINT-5 trial.

Read more

Weight loss with new obesity drug amycretin

Tirzepatide significantly reduces UACR in individuals with obesity and type 2 diabetes

Liraglutide reduces BMI for young children with obesity

» View more highlights on the EASD 2024 hub page

2024 ESC Congress

Noise pollution dangerous for heart health

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Read more

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits